Micreos Pharma announces success of its antibacterial enzyme that “selectively eliminates” pathogens

  18 April 2022

Micreos Pharmaceuticals’s novel antibacterial enzyme has been proved to be effective in selectively targeting and killing the harmful Staphylococcus aureus bacterial pathogen, as per the company’s study findings which it announced on Saturday. 

According to the company, the enzyme, XZ.700, eliminated the pathogen while maintaining a healthy microbiome and preventing antimicrobial resistance (AMR). These findings can be a crucial step in tackling AMR.

The pharma company maintained that XZ.700 is the first of many innovative endolysins in its portfolio and it’s essential as the first molecule the company will market. The findings of the study were published in Antimicrobial Agents and Chemotherapy.

Further reading: FE Healthcare
Author(s): FE Healthcare
Healthy Patients   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 550 AMR professionals and students in 60 countries!

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!
Popup Plugin